Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Name: Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
Author: Chamoun, Kamal

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. — المؤلف: Chamoun, Kamal — Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20200701

المؤلف: Chamoun, Kamal
النشر: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20200701
الوصف: 1347-1354 p.
الموضوعات: Adult؛ Age Factors؛ Aged؛ Allografts؛ Antineoplastic Combined Chemotherapy Protocols؛ Bortezomib؛ Carmustine؛ Cytarabine